ArticleMaterials today. Bio2026
Photopolymerizable placenta-derived ECM hydrogel enhances hUC-MSC-mediated wound healing via coordinated immunomodulation and angiogenesis.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal/stem cells (MSCs) hold great promise for regenerative medicine due to their potent immunomodulatory properties and favorable safety profile. However, their low survival, poor retention, and limited engraftment in injured tissues remain major barriers to clinical efficacy. Here, we engineered a photopolymerizable composite hydrogel derived from human placental extracellular matrix (PEM) and methacrylated hyaluronic acid (HAMA) to provide a biomimetic three-dimensional microenvironment for human umbilical cord MSCs (hUC-MSCs). The resulting PEM/HAMA (PH) hydrogel formed an interconnected porous, cytocompatible, and mechanically stable scaffold that enabled uniform cell encapsulation and maintained hUC-MSC viability above 80% after 72 h of culture. In
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.